The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originally randomized and treated with zofenopril and in 43.8% of patients treated with ramipril [odds ratio (OR) and 95% confidence interval, 0.65 (0.43-0.98), P = 0.041]. Such a result was achieved through a significantly larger reduction in CV hospitalization under zofenopril [OR: 0.61 (0.37-0.99), P = 0.047], whereas reduction in mortality rate with zofenopril did not achieve statistical significance versus ramipril [OR: 0.75 (0.36-1.59), P = 0.459]. These results were in line with those achieved during the initial 1-year follow-up. Benefits of early treatment of patients with LVD after acute myocardial infarction with zofenopril are sustained over many years as compared to ramipril.

Borghi, C., Omboni, S., Novo, S., Vinereanu, D., Ambrosio, G., Ambrosioni, E. (2017). Early Treatment with Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Patients with Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 69(5), 298-304 [10.1097/FJC.0000000000000473].

Early Treatment with Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Patients with Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study

Novo, Salvatore;
2017-01-01

Abstract

The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid. We now report CV outcomes during a 5-year follow-up of the patients of the SMILE-4 study. Three hundred eighty-six of the 518 patients completing the study (51.2%) could be tracked after the study end and 265 could be included in the analysis. During the 5.5 (±2.1) years of follow-up, the primary endpoint occurred in 27.8% of patients originally randomized and treated with zofenopril and in 43.8% of patients treated with ramipril [odds ratio (OR) and 95% confidence interval, 0.65 (0.43-0.98), P = 0.041]. Such a result was achieved through a significantly larger reduction in CV hospitalization under zofenopril [OR: 0.61 (0.37-0.99), P = 0.047], whereas reduction in mortality rate with zofenopril did not achieve statistical significance versus ramipril [OR: 0.75 (0.36-1.59), P = 0.459]. These results were in line with those achieved during the initial 1-year follow-up. Benefits of early treatment of patients with LVD after acute myocardial infarction with zofenopril are sustained over many years as compared to ramipril.
2017
Borghi, C., Omboni, S., Novo, S., Vinereanu, D., Ambrosio, G., Ambrosioni, E. (2017). Early Treatment with Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Patients with Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 69(5), 298-304 [10.1097/FJC.0000000000000473].
File in questo prodotto:
File Dimensione Formato  
Early Treatment With Zofenopril and Ramipril in.pdf

Solo gestori archvio

Dimensione 279.04 kB
Formato Adobe PDF
279.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10447/298391
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact